A Phase 1 interventional study of [¹⁴C]FXS4640 in Healthy Subjects, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Single-center, Non-randomized, Open-label, Single-dose Mass Balance Study of [14C]FXS4640 in Healthy Adult Male Participants
This study is a single-center, non randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C] FXS4640 in healthy adult male participants
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants meeting all of the following criteria may be enrolled:
Participants who meet any of the following criteria will not be enrolled:
Auxiliary Examinations:
Clinically significant abnormal results for surface antigen (HBsAg), virus antibody, treponema pallidum antibody, or antibody as judged by the investigator;
Medical and Medication History:
Symptomatic hemorrhoids or perianal diseases accompanied by regular/active hematochezia, irritable bowel syndrome, or inflammatory bowel disease;
Lifestyle Habits:
Have special dietary requirements or are unable to comply with the standardized diet (e.g., intolerance to standard meals); or refusal to abstain from pomelo/grapefruit or their juices, coffee, tea, any caffeine- or xanthine-rich foods (e.g., animal offal, seafood, soy products, etc.) or beverages from 48 hours before dosing until the end of the study;
Others:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mass balance Arm
Drug: [¹⁴C]FXS4640
Participants will receive a single oral administration of approximately 30 mg/200 μCi \[¹⁴C\]FXS4640 under fasting conditions on day 1 morning
Total radiorecovery and cumulative radiorecovery in urine and feces per time interval
To assess the routes and rates of elimination of FXS4640 and its metabolites after single oral administration of \[14C\]FXS4640 in healthy adult male participants.
Time frame: All excreted urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection
The percentage of plasma total radioactivity exposure accounted for by the parent compound and its metabolites (%AUC)
To evaluate the percentage of plasma total radioactivity exposure accounted for by the parent compound and its metabolites
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
The percentage of the administered dose recovered as parent drug and metabolites in urine and feces
To evaluate the percentage of the administered dose recovered as parent drug and metabolites in urine and feces, Identification of major metabolites in human urine and feces.
Time frame: Urine and feces samples from pre-dose to Day 21(504 hours) or meet the protocol-specified criteria for termination of sample collection
total radioactivity in human plasma and whole blood (if applicable)
To evaluate total radioactivity in human plasma and whole blood (if applicable) ,
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
the concentration ratio of total radioactivity in whole blood to that in plasma at different time points
To evaluate the concentration ratio of total radioactivity in whole blood to that in plasma at different time points
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
Cmax
To evaluate the Cmax of FXS4640 and its metabolite(if applicable) in plasma.
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
Tmax
To evaluate the Tmax of FXS4640 and its metabolite(if applicable) in plasma.
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
AUC0-t
To evaluate the AUC0-t of FXS4640 and its metabolite(if applicable) in plasma.
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
AUC0-∞
To evaluate the AUC0-∞ of FXS4640 and its metabolite(if applicable) in plasma.
Time frame: Plasma samples from pre-dose to Day 10(240 hours) or meet the protocol-specified criteria for termination of sample collection
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
To assess the safety and tolerability of a single oral dose of approximately \[14C\] FXS4640 in healthy adult male subjects
Time frame: Up to end of the study, approximately 2 months
Start is estimated for Oct 2026; primary completion for Nov 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. →